CUE - Cue Biopharma, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Currency in USD

Valuation measures

Market cap (intra-day) 5370.01M
Enterprise value 3289.75M
Trailing P/E N/A
Forward P/E 1-9.94
PEG ratio (5-yr expected) 1N/A
Price/sales (ttm)106.99
Price/book (mrq)6.78
Enterprise value/revenue 383.78
Enterprise value/EBITDA 6-8.06

Trading information

Stock price history

Beta (5Y monthly) 1.24
52-week change 333.89%
S&P500 52-week change 3-14.06%
52-week high 322.82
52-week low 36.54
50-day moving average 315.91
200-day moving average 313.00

Share statistics

Avg vol (3-month) 3240.65k
Avg vol (10-day) 3306.58k
Shares outstanding 522.99M
Float 18.62M
% held by insiders 115.53%
% held by institutions 143.70%
Shares short (12 Mar 2020) 41.18M
Short ratio (12 Mar 2020) 44.99
Short % of float (12 Mar 2020) 46.25%
Short % of shares outstanding (12 Mar 2020) 44.45%
Shares short (prior month 13 Feb 2020) 41.05M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2019
Most-recent quarter (mrq)30 Dec 2019

Profitability

Profit margin 0.00%
Operating margin (ttm)-1,063.21%

Management effectiveness

Return on assets (ttm)-39.29%
Return on equity (ttm)-82.88%

Income statement

Revenue (ttm)3.46M
Revenue per share (ttm)0.16
Quarterly revenue growth (yoy)217.40%
Gross profit (ttm)-24.03M
EBITDA -35.96M
Net income avi to common (ttm)-36.7M
Diluted EPS (ttm)-1.66
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)59.41M
Total cash per share (mrq)2.23
Total debt (mrq)5.8M
Total debt/equity (mrq)10.62
Current ratio (mrq)5.24
Book value per share (mrq)2.06

Cash flow statement

Operating cash flow (ttm)-30.8M
Levered free cash flow (ttm)-10.57M